What This MannKind Director Signals Risk to Royalties
A single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
Young adults can benefit from starting retirement planning early. Discover the best retirement plans tailored for your age group.
25,196 articlesA single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Insider trading activity can reveal how executives view their company’s future. This article digs into a real-world c...
As BioHarvest gears up for its Q1 2026 earnings, investors seek clarity on revenue momentum, margins, and the path to...
Could SpaceX stock reach $192 by 2027? This guide lays out the drivers, the math behind the target, and realistic ste...
A major fund manager disclosed a sizable sale of Invesco KBW Bank ETF shares, trimming exposure to U.S. banks. This a...
The federal debt breached $39 trillion this week as lawmakers debated a constitutional fix that failed to pass. The p...
When a company reports Q1 2026 results, the earnings call is where plans meet numbers. This guide explains how to rea...
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Headlines promising simple truths about markets often mislead. This article shows how prices reflect many signals ove...
Institutional hands move in the ETF space as second line capital buys into a short-maturity strategy. This article br...
A dramatic one-day move put Relay Therapeutics in the spotlight. After encouraging Phase 2 results for zovegalisib an...